Trial · NCT06034418
Efficacy of Pulse Radiofrequency Treatment in Patients With Coxarthrosis
NCT06034418, Not applicable, Completed, Ankara City Hospital Bilkent
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Pulse Radiofrequency Treatment in Patients With Coxarthrosis. Trials, record NCT06034418. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06034418
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Pulse Radiofrequency Treatment in Patients With Coxarthrosis
- NCT number
- NCT06034418
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 28 participants, actual
- Lead sponsor
- Ankara City Hospital Bilkent
- Conditions
- Coxarthrosis; Primary
- Interventions
- Pulse radiofrequency treatment, Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine
- First posted
- 2023-09-13
- Last updated
- 2024-02-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analogue Scale (VAS) | baseline, week 2, week 4 and week 12 | Visual Analogue Scale (VAS) is one of the pain rating scales. The amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain. The VAS consists of a 10 cm line, with two end points representing 0 (no pain) and 10 (extreme pain). At rest, with movement, nighttime VAS scores and averages of them will be recorded. |
| Secondary | Active Range of Motion | baseline, week 2, week 4 and week 12 | Active ROM is a joint movement that can be achieved by active muscle contraction without the aid of external forces. It will be measured with a goniometer by physician. |
| Secondary | Passive Range of Motion | baseline, week 2, week 4 and week 12 | Passive ROM is joint motion that can be achieved with the help of external forces. It will be measured with a goniometer by physician. |
| Secondary | Harris Hip Score (HHS) | baseline, week 2, week 4 and week 12 | HHS is a measure of dysfunction for the hip joint. It consists of 4 parts including pain, function, absence of deformity and range of motion. Scores range from 0 to 100. Higher scores mean less dysfunction. |
| Secondary | Six Minute Walk Test | baseline, week 2, week 4 and week 12 | 6-minute walk test is used to measure the functional capacity of the person. A 30-meter-long, flat and hard-floored walking path is used. The start and end points are marked with cones. The distance that walked over 6 minutes will be recorded. Higher distance indicates better functional capacity. |
| Secondary | Short From-36 (SF-36) | baseline, week 2, week 4 and week 12 | Sf-36 is a questionare that measure health related quality of life. It includes 36 questions and assesses 8 health domains: physical functionality, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain and general health perceptions. Scores for each domain range from 0 to 100. A higher score identifies a better state of health. |
| Secondary | Number of analgesics | baseline, week 2, week 4 and week 12 | The number of analgesic drugs used daily by the patient is recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06034418
GET https://conductscience.org/api/trials/v1/NCT06034418/registered